PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
11-Mar-2025 Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology Xeltis
11-Mar-2025 Kuros Biosciences grows sales to CHF 75.6 million for 2024 Kuros Biosciences
11-Mar-2025 Original-Research: Cantourage Group SE (von NuWays AG) Cantourage Group SE
11-Mar-2025 Curatis Announces Formation of Distinguished Advisory Board Curatis Holding AG
11-Mar-2025 PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth PolyPeptide Group
11-Mar-2025 Galenica continues to grow in 2024 Galenica AG
10-Mar-2025 HIV Drugs Industry to Expand from USD 28.6 Billion in 2023 to USD 47.5 Bn by 2034 | States Transparency Market Research, Inc. Transparency Market Research
10-Mar-2025 OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain OKYO Pharma
10-Mar-2025 STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market STADA
10-Mar-2025 CNX Therapeutics Launches MISABRI PR (Pregabalin) Prolonged-Release Tablets for Neuropathic Pain Management in the UK CNX Therapeutics
10-Mar-2025 Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan Lundbeck
10-Mar-2025 Valo Therapeutics announces EUR 19m of investment funding and expanded clinical trials Valo Therapeutics
10-Mar-2025 ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 ViiV Healthcare
10-Mar-2025 Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Sanofi
10-Mar-2025 Curia Announces Strategic Refinancing to Support Continued Growth Curia
10-Mar-2025 DOUGLAS Group secures partial refinancing with German private placement of €200m Douglas AG
10-Mar-2025 Bioversys announces partial exercise of over-allotment option BioVersys AG
07-Mar-2025 Viromed Medical AG: Strategic healthcare investor acquires further shares in private placement Viromed Medical AG
07-Mar-2025 Original-Research: CLINUVEL Pharmaceuticals (von Parmantier & Cie. GmbH) CLINUVEL Pharmaceuticals
07-Mar-2025 BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden UCB